Sanofi wins $226m in funds to expand influenza vaccine capacity in US
Category: #headlines  By Anchal Solanki  Date: 2019-12-10
  • share
  • Twitter
  • Facebook
  • LinkedIn
Sanofi wins $226m in funds to expand influenza vaccine capacity in US
  • The agreement is supported by federal funds from BARDA
     
  • A new manufacturing unit is to be established to facilitate sustainable production

France based pharmaceutical company- Sanofi Pasteur has reportedly signed an agreement with the U.S. Department of Health and Human Services to increase the production capacity of company’s domestic pandemic influenza vaccines in Swiftwater, Pennsylvania.

The agreement is supported by federal funds received from the Biomedical Advance Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at HHS.

According to David Loew, Executive Vice President of Vaccines at Sanofi, the contract will allow the company to enhance the supply of flu vaccines under cases of pandemic influenza. Sanofi Pasteur is focusing on advancing influenza vaccine technology along with enhancing the manufacturing mechanism, the public-private partnership will furthermore help safeguard people from influenza, he added.

Apparently, the agreement will foster clinical development and manufacturing of a recombinant pandemic vaccine to prepare the world for a global pandemic situation. The investigational pandemic vaccine will use the same technology as that of Flublok® Quadrivalent – an influenza vaccine developed by Sanofi.  

Moreover, the contract will enlarge the company’s role as a leading solution for pandemic preparedness by adding both adjuvant and recombinant manufacturing along with the prevailing egg-based manufacturing technique.

For the record, Flublok Quadrivalent may be given to adults above the age of 18 and is proven to prevent more than 30% to 43% confirmed cases of the infection in people who are 50 years old and above, as compared to its alternate vaccine.

Flublok Quadrivalent is the sole and effective protein-based influenza treatment solution which is approved by the U.S. Food and Drug Administration (FDA), rendering a precise genetic match of hemagglutinin (HA) from each suggested vaccine virus. HA is primarily a protein that is key to stimulating immunity to influenza.  

Sanofi is a global biopharmaceutical firm that primarily focuses on providing support to people through their health challenges. The company aims at preventing illness with the help of vaccines, providing advanced treatment techniques to fight pain and reduce suffering.

 

Source Credits: http://www.news.sanofi.us/2019-12-09-Sanofi-awarded-226-million-by-US-government-to-expand-pandemic-influenza-preparedness

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Anchal Solanki

Anchal Solanki    

A civil engineer by qualification, Anchal Solanki forayed into the domain of content writing in the midst of her graduation, embarking on the career path of a successful freelancer. Equipped with a short-term experience in market research, Anchal currently writes news...

Read More >>

More News By Anchal Solanki

Shannon provides safe & reusable thermal blanket insulation for NDS
Shannon provides safe & reusable thermal blanket insulation for NDS
By Anchal Solanki

  Shannon blanket insulation can offer up to 85% heat loss reduction over a surface They can prove to be an energy saving solution while improving the safety Shannon Global Energy Solutions, a leading designer and builder of reusable therm...

SSE takeover of energy service arm from Ovo for £500M on the cards
SSE takeover of energy service arm from Ovo for £500M on the cards
By Anchal Solanki

SSE, the UK energy giant, has stated that it will soon complete the sale of its energy service arm to Ovo for £500 million, incorporating £400 million in cash and £100 million in loan notes. SSE sees this as an opportunity at hand t...

Apple snaps up AI start up Xnor.ai in a deal worth up about $200M
Apple snaps up AI start up Xnor.ai in a deal worth up about $200M
By Anchal Solanki

Apple has acquired a Seattle-based AI start up Xnor.ai that specializes in edge-based and low-power artificial intelligence tools. The acquisition is in line with Apple’s much-talked about procurement of Turi, a Seattle-based AI start up in 201...